Correction: Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal

PDF  |  How to cite

Oncotarget. 2018; 9:29284-29284. https://doi.org/10.18632/oncotarget.25721

Metrics: PDF 1395 views  |   ?  

Abhishek D. Garg1, Sanne Elsen2, Dmitri V. Krysko3,4, Peter Vandenabeele3,4, Peter de Witte2 and Patrizia Agostinis1

1Cell Death Research & Therapy (CDRT) Unit, Department of Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium
2Laboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
3Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
4Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

Published: June 26, 2018

This article has been corrected: The correct Supplementary Figure S2C is given below. The authors' explanation is as follows:

Due to erroneous figure processing and oversight, unintended mistakes occurred during the assembly of Supplementary Figure S2C - specifically, the BiP/Grp78, CHOP and Actin panels for the AY27-PDT samples only. Using the source/raw data, we have now generated the correct Supplementary Figure S2C.

The authors apologize for the oversight. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript.

Original article: Oncotarget. 2015; 6:26841-26860. DOI: https://doi.org/10.18632/oncotarget.4754.

Supplementary Figure S2: Rat bladder carcinoma AY27 cells were treated or not (i.e. untreated controls/CNTR) with Hypericin-based Photodynamic Therapy (Hyp-PDT; 150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or mitoxantrone (MTX; 1 μM). C. immunoblotting for other ER stress markers like upregulation of BiP/GRP78 or CHOP levels at indicated recovery time-points. The calculations based on band densitometry analysis are mentioned as applicable.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25721